14/04/2021 – AB Science today announces that it has received financing approval from Société Générale, Bpifrance and Banque Populaire for a total of EUR 6 million in the form of state-guaranteed loans Download PDF Post navigationPreviousPrevious post:Signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19NextNext post:Masitinib Phase 2B/3 study in prostate cancer met its primary endpointRelated PostsAB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus29 November 2021AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia22 November 2021AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS18 November 2021AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)18 October 2021AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)4 October 2021Revenues for the first half of 2021 and update on AB Science’s activities30 September 2021
AB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus29 November 2021
AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia22 November 2021
AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS18 November 2021
AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)18 October 2021
AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)4 October 2021
